NASDAQ:GMTX Gemini Therapeutics (GMTX) Stock Price, News & Analysis $79.90 +2.24 (+2.88%) As of 10/27/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsFinancialsSEC Filings About Gemini Therapeutics Stock (NASDAQ:GMTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Gemini Therapeutics alerts:Sign Up Key Stats Today's Range$76.50▼$80.5050-Day Range$55.74▼$82.6752-Week Range$1.16▼$14.10Volume1.47 million shsAverage Volume189,291 shsMarket Capitalization$3.46 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Gemini Therapeutics, Inc. was a clinical-stage biotechnology company focused on developing precision medicines for genetically defined diseases, with an initial emphasis on ophthalmic conditions. The company sought to use insights from human genetics to identify therapeutic targets and develop treatments for patients with serious retinal disorders. Gemini’s lead program was GEM103, a recombinant form of complement factor H designed to address dysregulation of the complement system. The program was investigated as a potential treatment for geographic atrophy, an advanced form of dry age-related macular degeneration, and other diseases associated with complement-factor-H biology. Gemini Therapeutics combined with Disc Medicine in 2021. Following the transaction, the combined company operated under the Disc Medicine name and focused on hematology programs, meaning Gemini Therapeutics no longer operates as a standalone public company. The company’s historical activities were primarily directed toward the development of genetically targeted therapies rather than the marketing of commercially available products.AI Generated. May Contain Errors. Read More Receive GMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMTX Stock News HeadlinesGemini Therapeutics (NASDAQ:GMTX) Stock Price Up 4.2% - What's Next?October 28 at 2:21 AM | americanbankingnews.comFDA reversals leave investors worrying about the fates of other experimental drugsMarch 6, 2026 | cnbc.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 28 at 1:00 AM | Weiss Ratings (Ad)What Is Gemini? Everything You Should Know About Google's AI ToolOctober 17, 2024 | cnet.comGemini Review 2024: Is This Crypto Exchange a Gem for Your Investments?July 22, 2024 | businessinsider.com(SPAC) Special Purpose Acquisition Investigation: PRDS, GMTX, SNTI, TNGX - Contact Shareholder Rights Law Firm Johnson FistelJune 24, 2023 | benzinga.comBronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Gemini Therapeutics, Inc. (GMTX) InvestigationJune 1, 2023 | barrons.comThe Winklevoss' Gemini terminates its yield product as dispute between the crypto exchange and DCG escalatesJanuary 13, 2023 | markets.businessinsider.comSee More Headlines GMTX Stock Analysis - Frequently Asked Questions How have GMTX shares performed this year? Gemini Therapeutics' stock was trading at $79.41 at the beginning of the year. Since then, GMTX stock has increased by 0.6% and is now trading at $79.90. How were Gemini Therapeutics' earnings last quarter? Gemini Therapeutics, Inc. (NASDAQ:GMTX) posted its earnings results on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04. How do I buy shares of Gemini Therapeutics? Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Gemini Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Advanced Micro Devices (AMD), FuelCell Energy (FCEL), Lucid Group (LCID), Micron Technology (MU), Ocugen (OCGN), Plug Power (PLUG) and Alibaba Group (BABA). Company Calendar Last Earnings11/15/2021Today10/28/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GMTX CIK1816736 Webwww.geminitherapeutics.com Phone415-877-4887FaxN/AEmployees30Year Founded2015Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$71.87 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.78% Return on Assets-35.88% Debt Debt-to-Equity RatioN/A Current Ratio71.49 Quick Ratio71.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.89 per share Price / Book27.65Miscellaneous Outstanding Shares43,328,000Free Float37,739,000Market Cap$3.46 billion OptionableNot Optionable Beta-0.12 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:GMTX) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | SponsoredNvidia's $550 Trillion ProblemDo not buy another AI stock until you've seen the arithmetic below. Nvidia is worth about $5.5 trillion. Al...Decentralized Masters | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredMy Deep Cut Pick Before Anthropic's IPOThe biggest IPO in history is likely just weeks away... at a valuation of up to $2 trillion Anthropic could ma...Crypto 101 Media | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
